L&K Biomed Ltd. (KOSDAQ:156100)
9,070.00
-280.00 (-2.99%)
At close: Mar 19, 2026
L&K Biomed Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -16,297 | 9,743 | -1,867 | -13,625 | -9,669 |
Depreciation & Amortization | 2,782 | 2,572 | 2,313 | 2,302 | 1,725 |
Loss (Gain) From Sale of Assets | -65.28 | -254.5 | -16.24 | 65.73 | -220.44 |
Asset Writedown & Restructuring Costs | - | - | 16.8 | 243.71 | 623.87 |
Loss (Gain) From Sale of Investments | -67.03 | -75.14 | -49.41 | - | -1,684 |
Loss (Gain) on Equity Investments | 200 | 300 | 1,172 | 1,199 | 556.16 |
Stock-Based Compensation | - | 55.16 | 623.69 | 2,351 | 1,908 |
Provision & Write-off of Bad Debts | 821.67 | 766.88 | -413.62 | 521.54 | 374.33 |
Other Operating Activities | 16,321 | -8,549 | 669.6 | 1,522 | -2,473 |
Change in Accounts Receivable | -6,877 | 659.7 | -2,093 | -522.25 | 50.06 |
Change in Inventory | -8,790 | -6,944 | -1,139 | -1,522 | 1,257 |
Change in Accounts Payable | 1,280 | 1,646 | -389.97 | 1,843 | -1,725 |
Change in Other Net Operating Assets | -3,187 | -7,350 | -196.13 | -1,259 | -1,323 |
Operating Cash Flow | -13,879 | -7,430 | -1,370 | -6,881 | -10,600 |
Capital Expenditures | -2,991 | -584.84 | -2,047 | 196.74 | 98.75 |
Sale of Property, Plant & Equipment | 66.97 | 383.96 | 237.83 | - | 1,389 |
Cash Acquisitions | - | - | - | -3.75 | - |
Sale (Purchase) of Intangibles | -140.46 | -30.22 | -51.46 | -106.56 | 465.73 |
Investment in Securities | 13,000 | -8,880 | -4,243 | -2,560 | 3,229 |
Other Investing Activities | 63.39 | 9.92 | -9.09 | -27.94 | -32.26 |
Investing Cash Flow | 10,363 | -9,001 | -6,413 | -2,502 | 5,301 |
Short-Term Debt Issued | 3,626 | 1,500 | 7,136 | 1,345 | 1,533 |
Long-Term Debt Issued | 3,884 | 20,102 | 1,700 | - | 21,700 |
Total Debt Issued | 7,510 | 21,602 | 8,836 | 1,345 | 23,233 |
Short-Term Debt Repaid | -2,851 | -1,590 | -7,148 | - | -7,206 |
Long-Term Debt Repaid | -2,944 | -2,443 | -21,393 | -711.84 | -4,144 |
Total Debt Repaid | -5,795 | -4,033 | -28,541 | -711.84 | -11,350 |
Net Debt Issued (Repaid) | 1,715 | 17,569 | -19,705 | 632.73 | 11,884 |
Issuance of Common Stock | - | - | 25,334 | 100 | 1,348 |
Other Financing Activities | -56.92 | - | - | -0 | 3,121 |
Financing Cash Flow | 1,658 | 17,569 | 5,629 | 732.72 | 16,353 |
Foreign Exchange Rate Adjustments | 1,202 | -2,350 | -193.5 | -62.93 | 143.24 |
Miscellaneous Cash Flow Adjustments | 0 | - | -0 | - | - |
Net Cash Flow | -656.65 | -1,212 | -2,348 | -8,713 | 11,197 |
Free Cash Flow | -16,870 | -8,015 | -3,417 | -6,684 | -10,501 |
Free Cash Flow Margin | -43.34% | -22.21% | -11.43% | -33.81% | -68.31% |
Free Cash Flow Per Share | -830.21 | -368.54 | -210.77 | -498.99 | -784.49 |
Cash Interest Paid | 1,116 | 1,090 | 840.52 | 635.93 | 552.66 |
Cash Income Tax Paid | -158.14 | 94.5 | 329.24 | -22.33 | 0.1 |
Levered Free Cash Flow | -8,884 | -4,469 | -9,869 | -252.54 | 619.25 |
Unlevered Free Cash Flow | -6,964 | -2,794 | -8,618 | 1,126 | 1,482 |
Change in Working Capital | -17,575 | -11,989 | -3,818 | -1,460 | -1,741 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.